Lantern Pharma Inc. (LTRN) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Lantern Pharma reported revenue of $0. Net income was -$17.1M, or -$1.57 per diluted share. Operating activities generated -$15.7M of cash, leaving -$15.7M of free cash flow. At fiscal year end, Lantern Pharma held $11.0M in total assets against $4.5M in total liabilities, including $4.4M of cash and equivalents.
Open the full interactive Lantern Pharma financials → Quarterly statements, key ratios, valuation history and price charts.
Lantern Pharma Key Stats
| Share Price | $0.71 |
|---|---|
| Market Cap | $8.8M |
| 52-Week Range | $0.71 – $4.42 |
| Shares Outstanding | 12.4 million (basic, 2026 Q2) |
Lantern Pharma Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating Income | — | — | -$14.4M | -$17.9M | -$22.2M | -$18.0M |
| Pre-Tax Income | -$5.9M | -$12.4M | -$14.3M | -$16.0M | -$20.8M | -$17.1M |
| Net Income | -$5.9M | -$12.4M | -$14.3M | -$16.0M | -$20.8M | -$17.1M |
| Diluted EPS | -$1.37 | -$1.13 | — | -$1.47 | -$1.93 | -$1.57 |
Lantern Pharma Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$4.2M | -$4.1M | -$3.3M | -$7.1M |
| Diluted EPS | -$0.39 | -$0.37 | -$0.30 | -$0.57 |
Lantern Pharma Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $19.2M | $51.5M | $37.2M | $21.9M | $7.5M | $4.4M |
| Current Assets | $20.2M | $72.7M | $58.7M | $43.3M | $25.2M | $10.8M |
| Total Assets | $20.4M | $74.0M | $58.8M | $43.6M | $25.6M | $11.0M |
| Current Liabilities | $552,339 | $2.3M | $2.8M | $2.7M | $4.3M | $4.5M |
| Total Liabilities | $660,839 | $2.4M | $2.8M | $2.7M | $4.4M | $4.5M |
| Shareholders' Equity | $19.7M | $71.6M | $56.0M | $40.9M | $21.2M | $6.5M |
Lantern Pharma Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$5.7M | -$10.6M | -$12.8M | -$14.3M | -$17.8M | -$15.7M |
| Cash From Investing | -$16,137 | -$19.5M | $179,268 | -$930,210 | $3.4M | $11.1M |
| Cash From Financing | $23.7M | $63.4M | -$2.2M | -$499,997 | $66,710 | $1.5M |
| Free Cash Flow | — | — | -$12.8M | -$14.4M | -$17.8M | -$15.7M |
Figures from Lantern Pharma's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Lantern Pharma financials page for every line item.
Lantern Pharma Company Profile
| Ticker | LTRN |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Dallas, Texas |
| Incorporated in | Texas |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001763950 |
Frequently Asked Questions
What was Lantern Pharma's revenue in fiscal 2025?
Lantern Pharma (LTRN) reported revenue of $0 for fiscal 2025.
What is Lantern Pharma's annual revenue history?
Lantern Pharma's annual revenue by fiscal year: 2020: $0; 2021: $0; 2022: $0; 2023: $0; 2024: $0; 2025: $0.
What was Lantern Pharma's net income in fiscal 2025?
Lantern Pharma reported net income of -$17.1M for fiscal 2025.
What was Lantern Pharma's earnings per share (EPS) in fiscal 2025?
Lantern Pharma's diluted EPS was -$1.57 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Lantern Pharma generate in fiscal 2025?
Lantern Pharma generated -$15.7M of free cash flow in fiscal 2025.
What was Lantern Pharma's revenue last quarter?
In its most recent reported quarter (2026 Q2), Lantern Pharma reported revenue of $0.
How many shares of Lantern Pharma are outstanding?
Lantern Pharma reported a weighted average of 12.4 million basic shares outstanding in 2026 Q2.
What is Lantern Pharma's market cap?
Based on its latest closing price, Lantern Pharma (LTRN) has a market capitalization of about $8.8M.
When does Lantern Pharma's fiscal year end?
Lantern Pharma's fiscal year end, as registered with the SEC, is December 31.
Where is Lantern Pharma headquartered?
Lantern Pharma lists its business address in Dallas, Texas in its SEC filings.